Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
2016-004147-37Phase 2Completed
- Sponsor
- Clinical Trials Center Aachen
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ferric carboxymaltose in heart failure with reduced ejection fraction (HFrEF), iron deficiency anemia (IDA), chronic kidney disease (CKD), sponsored by Clinical Trials Center Aachen. Started Nov 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with reduced ejection fraction (HFrEF)iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-004147-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004147-37.